ERBIN as A Potential Drug Target for Neurological Disorders (G55914)

Target Name: ERBIN

NCBI ID: G55914

ERBIN

ERBIN as A Potential Drug Target for Neurological Disorders

ERBIN (KIAA1225) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. It is a key player in the potassium/calbindin (KCa2+) signaling pathway, which is involved in a wide range of physiological processes in the brain, including neurotransmitter release, synaptic plasticity, and stress response.

Recent studies have identified ERBIN as a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. By blocking the effects of ERBIN, researchers have been able to reduce the amount of neurotransmitter-related protein in the brain, which can slow down the progression of cognitive decline and improve overall neurological function.

One of the key benefits of targeting ERBIN is its potential to treat Alzheimer's disease specifically. Unlike other neurological disorders, Alzheimer's disease is characterized by the accumulation of neurotransmitter-related protein in the brain, which is thought to contribute to the development and progression of the disease. By targeting ERBIN, researchers have been able to reduce the amount of neurotransmitter-related protein in the brain and slow down the progression of cognitive decline.

Another potential benefit of ERBIN targeting is its potential to treat other neurological disorders. While ERBIN is primarily expressed in the brain, it is also expressed in other tissues and has been shown to play a role in a wide range of physiological processes, including inflammation, pain, and stress response. By targeting ERBIN, researchers have been able to investigate its potential as a drug target for a wide range of neurological disorders.

Targeting ERBIN also has the potential to be a valuable diagnostic tool. By measuring the amount of ERBIN in brain tissue, researchers have been able to determine the effectiveness of different treatments for Alzheimer's disease and other neurological disorders. This information can be used to develop more effective treatments and to monitor the effectiveness of new treatments.

In conclusion, ERBIN (KIAA1225) is a protein that is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. It is a key player in the potassium/calbindin (KCa2+) signaling pathway and has has been shown to be a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. Further research is needed to fully understand the role of ERBIN in neurological disease and to develop more effective treatments.

Protein Name: Erbb2 Interacting Protein

Functions: Acts as an adapter for the receptor ERBB2, in epithelia. By binding the unphosphorylated 'Tyr-1248' of receptor ERBB2, it may contribute to stabilize this unphosphorylated state (PubMed:16203728). Inhibits NOD2-dependent NF-kappa-B signaling and pro-inflammatory cytokine secretion (PubMed:16203728)

The "ERBIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERBIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets